Literature DB >> 11322505

Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.

C Y Bowers1, R Granda-Ayala.   

Abstract

To better appreciate the interactions of GHRP-2 and GHRH 1-44NH2 on the release of GH in normal adult men and women with decreased GH secretion and low serum IGF-1 levels, a series of acute and chronic studies have been performed (n = 5 men, 5 women). The acute iv bolus GH responses of these subjects to the two peptides alone and together suggest that the decreased GH secretion may be primarily due to a deficiency of the natural endogenous GHRP, ghrelin, rather than a decreased secretion of endogenous GHRH or excess secretion of SRIF. To determine whether the low GH response to GHRH was due to a limited capacity of pituitary to release GH, higher dosages of GHRP-2 alone were administered. At a dose of 1 microg/kg GHRP-2 the GH response was essentially the same as that elicited by 1 microg/kg GHRH + 0.1 microg/kg GHRP-2 while the GH response to 10 microg/kg GHRP-2 sc was about twice as high in both men and women. Although these subjects have a limited pituitary capacity to release GH, which is also an indication of decreased GH secretion in the presence of low serum IGF-1 levels, this alone would not explain the low GH response to GHRH. Furthermore, the finding that a low dose of 0.1 microg/kg GHRP-2 augments the GH response to 1 microg/kg GHRH is strongly against an excess secretion of SRIF. Twenty-four hour profiles of GH secretion during placebo, GHRP-2, and various doses of GHRH alone and together with GHRP-2 were studied. In addition, 1 microg/kg/h GHRP-2 was infused continuously sc to these subjects for 30 d. The normal pulsatile secretion of GH as well as the serum IGF-1 level was increased after 24 h and remained elevated for 30 d. With a deficiency of endogenous GHRH, the GH response of GHRP-2 would be little to none, while in subjects with a deficiency of the natural GHRP, the GH response to GHRH would be more attenuated. Thus, in chronic deficiency the GH response would be expected to depend on the degree of the capacity of the pituitary to release GH as well as the type(s) of hormonal deficiency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11322505     DOI: 10.1385/ENDO:14:1:079

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  9 in total

1.  Hypothalamic growth hormone secretagogue-receptor (GHS-R) expression is regulated by growth hormone in the rat.

Authors:  P A Bennett; G B Thomas; A D Howard; S D Feighner; L H van der Ploeg; R G Smith; I C Robinson
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

Review 2.  Growth hormone-releasing peptide (GHRP).

Authors:  C Y Bowers
Journal:  Cell Mol Life Sci       Date:  1998-12       Impact factor: 9.261

3.  Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6.

Authors:  S L Dickson; S M Luckman
Journal:  Endocrinology       Date:  1997-02       Impact factor: 4.736

4.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

5.  The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture.

Authors:  K Cheng; W W Chan; A Barreto; E M Convey; R G Smith
Journal:  Endocrinology       Date:  1989-06       Impact factor: 4.736

6.  Growth hormone-releasing hexapeptide is a potent stimulator of growth hormone gene expression and release in the growth hormone-releasing hormone-deprived infant rat.

Authors:  V Locatelli; R Grilli; A Torsello; S G Cella; W B Wehrenberg; E E Müller
Journal:  Pediatr Res       Date:  1994-08       Impact factor: 3.756

7.  A receptor in pituitary and hypothalamus that functions in growth hormone release.

Authors:  A D Howard; S D Feighner; D F Cully; J P Arena; P A Liberator; C I Rosenblum; M Hamelin; D L Hreniuk; O C Palyha; J Anderson; P S Paress; C Diaz; M Chou; K K Liu; K K McKee; S S Pong; L Y Chaung; A Elbrecht; M Dashkevicz; R Heavens; M Rigby; D J Sirinathsinghji; D C Dean; D G Melillo; A A Patchett; R Nargund; P R Griffin; J A DeMartino; S K Gupta; J M Schaeffer; R G Smith; L H Van der Ploeg
Journal:  Science       Date:  1996-08-16       Impact factor: 47.728

8.  Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.

Authors:  E Ghigo; L Gianotti; E Arvat; J Ramunni; M R Valetto; F Broglio; M Rolla; F Cavagnini; E E Müller
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

9.  Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.

Authors:  C A Jaffe; P J Ho; R Demott-Friberg; C Y Bowers; A L Barkan
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

  9 in total
  3 in total

1.  Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake.

Authors:  Blandine Laferrère; Allison B Hart; Cyril Y Bowers
Journal:  Obesity (Silver Spring)       Date:  2006-06       Impact factor: 5.002

2.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

Review 3.  Growth hormone-releasing hormone and growth hormone secretagogues in normal aging.

Authors:  George R Merriam; Robert S Schwartz; Michael V Vitiello
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.